Stocksigma LogoStocksigma Logo

Symbiotec Pharmalab Q2 & H1FY27 Performance and Growth Strategy Presentation

Symbiotec Pharmalab reported consolidated revenue of INR 280 cr in Q2FY27 (up 43% YoY) and INR 498 cr in H1FY27 (up 25% YoY)

Symbiotec Pharmalab Q2 & H1FY27 Performance and Growth Strategy Presentation

Symbiotec Pharmalab Ltd · Investor Presentation · 06 Nov 2026, 1:50 am

Symbiotec Pharmalab Q2 & H1FY27 Performance and Growth Strategy Presentation Symbiotec Pharmalab reported consolidated revenue of INR 280 cr in Q2FY27 (up 43% YoY) and INR 498 cr in H1FY27 (up 25% YoY). Q2 EBITDA surged 88% YoY to INR 94 cr (adjusted), with PAT up 169% YoY to INR 52 cr, driven by steady API sales and INR 53 cr licensing milestone income. Over INR 1,000 cr capex in complex injectables and CDMO services is set to generate revenue over the next 6–12 months, backed by take-or-pay pacts and pending US ANDA filings.

Original exchange filing (PDF)

More announcements from Symbiotec Pharmalab Ltd

All Symbiotec Pharmalab Ltd announcements